bioRxivCancer BiologyPreprint
A FOXA1/SPDEF Co-regulatory Axis Drives ERBB2 and Suppresses TEAD/YAP-Driven EMT to Maintain Luminal Identity in HER2+ Breast Cancer
Jaekwang JeongiD, Jongwon Lee, Seungsoo KimiD, Jaechul Lim, Jaehun Shin, Kwangmin YooiD, Jonghun Kim, Yoshiaki TanakaiD, Hyun Seop Tae, Lark Kyun Kim, In-Hyun Park, Samir ZaidiiD, John Wysolmerski, Jungmin ChoiiD
Abstract
The function of the pioneer factor forkhead box A1 (FOXA1) in estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 gene)-positive breast cancer represents a critical gap in our understanding of lineage identity in tumorigenesis. Here, we solve this enigma by addressing this question through the identification of an indispensable, co-dependent regulatory circuit formed between FOXA1 and the SAM pointed domain containing ETS-family transcription factor (SPDEF). Using integrative multi-omics analyses of patient tumors and experimental models, we demonstrate that this circuit functions as the master guardian of the HER2-positive luminal state. It executes this role via two distinct, essential mechanisms: it directly binds regulatory elements to drive high-level expression of the ERBB2 oncogene, and it simultaneously preserves epithelial identity by suppressing a latent program of epithelial-to-mesenchymal transition (EMT). Mechanistically, the FOXA1/SPDEF circuit promotes the expression of the transcriptional repressor TRPS1, which in turn antagonizes the pro-mesenchymal activity of the TEAD/YAP complex. Our findings define a central regulatory node that couples lineage fidelity to oncogenic output in HER2-positive cancer, revealing the FOXA1/SPDEF-TRPS1 axis as a critical determinant of tumor plasticity and a potential therapeutic target for overcoming resistance in HER2-positive breast cancer.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1
S. Gilfillan, S. Wang, … A. Hurtado-Rodriguez·bioRxiv·Sep 22, 2020
- Synergistic interplay between PHF8 and HER2 signaling contributes to breast cancer development and drug resistance
- The transcription factor AP-2β defines active enhancers conferring molecular apocrine cell identity in breast cancer
Ebtihal H Mustafa, Geraldine Laven‐Law, … Theresa E. Hickey·bioRxiv·Jul 5, 2025
- Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer
B. Nami, A. Ghanaeian, Z. Wang·bioRxiv·Mar 24, 2020
- Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer
Jaekwang Jeong, Kwangmin Yoo, … John J. Wysolmerski·Breast Cancer ResearchPeer-reviewed·May 19, 2025
- ERBB2/HOXB13 co-amplification with interstitial deletion of BRCA1 defines a unique subset of breast cancers
Irene Rin Mitsiades, Maristela Lika Onozato, … Esther Rheinbay·bioRxiv·Aug 4, 2024